Evidence map›Paper›PMID 37711632›Full record

Observational studyFrontiers in immunology2023

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability.

Elizabeth K Graydon, Tonia L Conner, Kim Dunham, Cara Olsen, Emilie Goguet, Si'Ana A Coggins, Marana Rekedal, Emily Samuels, Belinda Jackson-Thompson, Matthew Moser and 23 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Real-life observation of wildfire smoke-impaired COVID-19 vaccine immunity.The Journal of allergy and clinical immunology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 5 institutions in 1 country.

Elizabeth K GraydonDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Tonia L ConnerDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Kim DunhamFrederick National Laboratory for Cancer Research, Frederick, MD, United States.
Cara OlsenDepartment of Preventive Medicine & Biostatistics, Uniformed Services University, Bethesda, MD, United States.
Emilie GoguetDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Si'Ana A CogginsDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Marana RekedalDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Emily SamuelsDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Belinda Jackson-ThompsonDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Matthew MoserDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Alyssa LindroseDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Monique Hollis-PerryClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center (NMRC), Silver Spring, MD, United States.
Gregory WangClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center (NMRC), Silver Spring, MD, United States.
Santina MaiolatesiHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Yolanda AlcortaClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center (NMRC), Silver Spring, MD, United States.
Anatalio ReyesClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center (NMRC), Silver Spring, MD, United States.
Mimi WongClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center (NMRC), Silver Spring, MD, United States.
Kathy RamseyClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center (NMRC), Silver Spring, MD, United States.
Julian DaviesHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Edward ParmeleeHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Orlando OrtegaHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Mimi SanchezHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Sydney MollerFrederick National Laboratory for Cancer Research, Frederick, MD, United States.
Jon InglefieldFrederick National Laboratory for Cancer Research, Frederick, MD, United States.
David TribbleInfectious Disease Clinical Research Program, Department of Preventive Medicine & Biostatistics, Uniformed Services University, Bethesda, MD, United States.
Timothy BurgessInfectious Disease Clinical Research Program, Department of Preventive Medicine & Biostatistics, Uniformed Services University, Bethesda, MD, United States.
Robert O'ConnellInfectious Disease Clinical Research Program, Department of Preventive Medicine & Biostatistics, Uniformed Services University, Bethesda, MD, United States.
Allison M W MalloyDepartment of Pediatrics, Uniformed Services University, Bethesda, MD, United States.
Simon PollettHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Christopher C BroderDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Eric D LaingDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Stephen K AndersonFrederick National Laboratory for Cancer Research, Frederick, MD, United States.
Edward MitreDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, United States.
Uniformed Services University of the Health Sciences · USHenry M. Jackson Foundation · USFrederick National Laboratory for Cancer Research · USGeneral Dynamics (United States) · USNaval Medical Research Command · US

Funding

NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Introduction: Natural killer (NK) cells can both amplify and regulate immune responses to vaccination. Studies in humans and animals have observed NK cell activation within days after mRNA vaccination. In this study, we sought to determine if baseline NK cell frequencies, phenotype, or function correlate with antibody responses or inflammatory side effects induced by the Pfizer-BioNTech COVID-19 vaccine (BNT162b2). Methods: We analyzed serum and peripheral blood mononuclear cells (PBMCs) from 188 participants in the Prospective Assessment of SARS-CoV-2 Seroconversion study, an observational study evaluating immune responses in healthcare workers. Baseline serum samples and PBMCs were collected from all participants prior to any SARS-CoV-2 infection or vaccination. Spike-specific IgG antibodies were quantified at one and six months post-vaccination by microsphere-based multiplex immunoassay. NK cell frequencies and phenotypes were assessed on pre-vaccination PBMCs from all participants by multi-color flow cytometry, and on a subset of participants at time points after the 1 Results: Key observations include: 1) circulating NK cells exhibit evidence of activation in the week following vaccination, 2) individuals with high symptom scores after 1 Discussion: These results suggest that NK cell activation by BNT162b2 vaccination may contribute to vaccine-induced inflammatory symptoms and reduce durability of vaccine-induced antibody responses.

Indexed as

COVID-19Drug-Related Side Effects and Adverse ReactionsAnimalsBNT162 VaccineHumansImmunoglobulin GLeukocytes, MononuclearmRNA VaccinesProspective StudiesSARS-CoV-2BNT162 VaccineImmunoglobulin GmRNA Vaccinesantibody durabilityCOVIDmRNA vaccineNK cellsreactogenicitySARS-CoV-2 vaccinevaccine side effects

Identifiers

PMID37711632
PMCPMC10497936
OpenAlexW4386156540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.